Geovax Labs is a biotechnology company that focuses on developing innovative vaccines and immunotherapies for infectious diseases and cancer. With a particular emphasis on addressing public health concerns, Geovax leverages its proprietary technology platform to create novel medical solutions aimed at enhancing immune responses. The company is involved in various stages of research and development, working to advance its projects through clinical trials and collaborations with other research entities, committed to improving health outcomes and combating significant health threats. Read More
Confirms Single Phase 3 Immuno-Bridging Trial Sufficient to Evaluate Efficacy and to Support a Marketing Authorization Application (MAA) For Vaccination against Mpox and Smallpox
Wondering how the US markets performed in the middle of the day on Wednesday? Discover the movers and shakers of today's session in our comprehensive analysis.
ATLANTA, GA - June 12, 2025 ( NEWMEDIAWIRE ) - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing multi-antigen vaccines and immunotherapies, today announced that company representatives will attend the 2025 BIO International Convention being held June 16-19, 2025 at the Boston Convention and Exhibition Center in Boston, Massachusetts.
ATLANTA, GA - June 10, 2025 ( NEWMEDIAWIRE ) - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing multi-antigen vaccines and immunotherapies against infectious diseases and solid tumors, today announced that clinical data for its next-generation COVID-19 multi-antigen vaccine candidate, GEO-CM04S1, will be presented at the European Hematology Association (EHA) 2025 Hybrid Congress, taking place June 12–15, 2025, in Milan, Italy and online.
